ADMA Biologics, Inc. operates as an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics for the treatment of immunodeficient patients at risk for infection, and others at risk for…
Analysis
Quality compounder
ADMA Biologics, Inc. is a quality compounder: a well-run business trading at a price that reflects what it is worth. One caution: reported profits have recently run ahead of actual cash, which we track closely.
The price is attractive. You pay 12.6× its owner earnings: the cash an owner could take out each year, which is in the historically attractive zone. At today's price, the market is assuming roughly 0% yearly growth; analysts expect 30%. The price, in other words, assumes less than the experts do.
The trajectory is moderate and the balance sheet is adequate. The company scores 12/20 on our value-creation score: creating some value.
What to watch: Some accounting patterns deserve a closer look. Some accounting patterns deserve a closer look. Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.
360° rank · history
1007550250
Mar 202680
92
2026
All-time high
92
Jun 2026
All-time low
80
Mar 2026
Average rank
86
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
83
—
—
—
Price/Earnings
27
—
—
—
Price/Book
50
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
45
—
—
—
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.